Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | DNM1 | Q05193 | 6/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14270566 | 1.00 | TSHR (0.40) | TSHRTHRBLMNADNM1ALDH1A1 | |
| SCHEMBL5711705 | 1.00 | TSHR (0.40) | TSHRTHRBLMNADNM1ALDH1A1 | |
| SCHEMBL1915388 | 1.00 | TSHR (0.40) | TSHRTHRBLMNADNM1ALDH1A1 | |
| SCHEMBL11926993 | 1.00 | TSHR (0.40) | TSHRTHRBLMNADNM1ALDH1A1 | |
| SCHEMBL1959828 | 1.00 | TSHR (0.40) | TSHRTHRBLMNADNM1ALDH1A1 | |
| SCHEMBL727806 | 1.00 | TSHR (0.40) | TSHRTHRBLMNADNM1ALDH1A1 | |
| SCHEMBL727830 | 1.00 | TSHR (0.40) | TSHRTHRBLMNADNM1ALDH1A1 | |
| SCHEMBL20477180 | 1.00 | TSHR (0.40) | TSHRTHRBLMNADNM1ALDH1A1 | |
| SCHEMBL21114738 | 1.00 | TSHR (0.40) | TSHRTHRBLMNADNM1ALDH1A1 | |
| SCHEMBL29766725 | 1.00 | TSHR (0.40) | TSHRTHRBLMNADNM1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724153-A1 | SUNSCREEN COMPOSITIONS AND METHODS OF USE | Mary Kay, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| US-20250262154-A1 | A NON-AQUEOUS SPRAY COMPOSITION | AMATERASU LIFESCIENCES LLP. (IN) | 2025-08-21 | — | — | US | claimed |
| EP-4566589-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND ALLEVIATION OF EARLY SKIN REACTIONS CAUSED BY IRRADIATION IN PATIENTS TREATED FOR CANCER | Verco Spolka Akcyjna (PL) | 2025-06-11 | — | — | EP | claimed |
| US-20240407996-A1 | SUNSCREEN COMPOSITIONS AND METHODS OF USE | MARY KAY INC. (US) | 2024-12-12 | — | — | US | claimed |
| WO-2024253961-A1 | SUNSCREEN COMPOSITIONS AND METHODS OF USE | MARY KAY INC. (US) | 2024-12-12 | — | — | WO | claimed |
| US-20260137615-A1 | Anhydrous Sunscreen Compositions With enhanced Ultraviolet Protection | ELC MAN LLC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4724153-A1 | SUNSCREEN COMPOSITIONS AND METHODS OF USE | Mary Kay, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12502339-B2 | Foam compositions | THE PROCTER & GAMBLE COMPANY (US) | 2025-12-23 | — | — | US | disclosed |
| EP-3719056-B1 | ORGANIC GROUP-MODIFIED ORGANOSILICON RESIN, PRODUCTION METHOD THEREOF, AND COSMETIC | SHINETSU CHEMICAL CO (JP) | 2025-08-27 | — | — | EP | disclosed |
| US-20250262154-A1 | A NON-AQUEOUS SPRAY COMPOSITION | AMATERASU LIFESCIENCES LLP. (IN) | 2025-08-21 | — | — | US | disclosed |
| EP-4566589-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND ALLEVIATION OF EARLY SKIN REACTIONS CAUSED BY IRRADIATION IN PATIENTS TREATED FOR CANCER | Verco Spolka Akcyjna (PL) | 2025-06-11 | — | — | EP | disclosed |
| EP-3768762-B1 | SILICONE POLYMER | MOMENTIVE PERFORMANCE MAT INC (US) | 2025-02-19 | — | — | EP | disclosed |
| US-10717887-B2 | Oil-based inkjet ink | RISO KAGAKU CORPORATION (JP) | 2020-07-21 | — | — | US | disclosed |
| US-20180244939-A1 | OIL-BASED INKJET INK | RISO KAGAKU CORPORATION (JP) | 2018-08-30 | — | — | US | disclosed |
| EP-3366737-A1 | OIL-BASED INKJET INK | Riso Kagaku Corporation (JP) | 2018-08-29 | — | — | EP | disclosed |
| US-9932446-B2 | Method of manufacturing a purified product of alkyl-modified polydimethylsiloxane, a cosmetic raw material, and cosmetics | DOW CORNING TORAY CO., LTD. (JP) | 2018-04-03 | — | — | US | disclosed |
| EP-1894994-B1 | Two or more phase face cleansing agent with improved reversible mixing and demixing solution | HENKEL AG & CO KGAA (DE) | 2013-10-16 | — | — | EP | disclosed |
| US-20120202893-A1 | Method Of Manufacturing A Purified Product Of Alkyl-Modified Polydimethylsiloxane, A Cosmetic Raw Material, And Cosmetics | DOW TORAY CO., LTD. (JP) | 2012-08-09 | — | — | US | disclosed |
| EP-1902704-A1 | Cosmetic compositions containing a combination of silicon-elastomers | Henkel KGaA (DE) | 2008-03-26 | — | — | EP | disclosed |
| EP-1894994-A1 | Two or more phase face cleansing agent with improved reversible mixing and demixing solution | Henkel KGaA (DE) | 2008-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12502339-B2 | Foam compositions | DSG1, DAGLA, DEK | TSHR 3631/4885THRB 4039/4885LMNA 3144/4885 |
| US-20260137615-A1 | Anhydrous Sunscreen Compositions With enhanced Ultraviolet Protection | OGFOD1, ERCC2, OGG1 | TSHR 4445/4885THRB 4262/4885LMNA 3563/4885 |
| US-20120202893-A1 | Method Of Manufacturing A Purified Product Of Alkyl-Modified Polydimethylsiloxane, A Cosmetic Raw Material, And Cosmetics | OR10J3, CUTA, DEGS1 | TSHR 3657/4885THRB 3548/4885LMNA 2103/4885 |
| US-20240407996-A1 | SUNSCREEN COMPOSITIONS AND METHODS OF USE | OGG1, RAD23B, RAD50 | TSHR 4116/4885THRB 3633/4885LMNA 1823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.